Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

被引：0
|
作者：
Li, Shuluan [1 ,2 ]
Zhang, Pei [3 ]
Wang, Tianyu [2 ,4 ]
Wang, Jie [3 ]
Duan, Jianchun [3 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol Natl,Canc Ctr, Shenzhen 100021, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Dept Breast Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China
来源：
THORACIC CANCER | 2021年 / 12卷 / 23期
关键词：
ALK; brigatinib; chemotherapy; lung squamous cell carcinoma; 1ST-LINE CRIZOTINIB; OPEN-LABEL; CANCER; ROS1;
D O I：
10.1111/1759-7714.14133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK-positive lung squamous cell carcinoma. The patient in this report was diagnosed with ALK-positive lung squamous cell carcinoma with brain metastases, and received brigatinib after failure of first-line chemotherapy. Response duration was approximately 11 months, with tolerable side effects. In conclusion, a good clinical effect was achieved in a patient with ALK positive lung squamous cell carcinoma who received treatment with an ALK inhibitor.
引用
收藏
页码：3273 / 3276
页数：4
相关论文
共 50 条
  • [1] Coexistence of squamous cell tracheal papilloma and carcinoma treated with chemotherapy and radiotherapy: a case report
    Paliouras, Dimitrios
    Gogakos, Apostolos
    Rallis, Thomas
    Chatzinikolaou, Fotios
    Asteriou, Christos
    Tagarakis, Georgios
    Organtzis, John
    Tsakiridis, Kosmas
    Tsavlis, Drosos
    Zissimopoulos, Athanasios
    Kioumis, Ioannis
    Hohenforst-Schmidt, Wolfgang
    Zarogoulidis, Konstantinos
    Zarogoulidis, Paul
    Barbetakis, Nikolaos
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1 - 3
  • [2] ALK-rearranged squamous cell lung cancer: a case report
    Zhang, Quan
    Wang, Jinghui
    Zhang, Shucai
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (02): : 2195 - 2198
  • [3] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
    Nobuaki Mamesaya
    Kazuhisa Nakashima
    Tateaki Naito
    Takashi Nakajima
    Masahiro Endo
    Toshiaki Takahashi
    BMC Cancer, 17
  • [4] ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
    Mamesaya, Nobuaki
    Nakashima, Kazuhisa
    Naito, Tateaki
    Nakajima, Takashi
    Endo, Masahiro
    Takahashi, Toshiaki
    BMC CANCER, 2017, 17
  • [5] Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report
    Yamamoto, Yoko
    Kodama, Ken
    Maniwa, Tomohiro
    Takeda, Masashi
    Kishima, Hiroki
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (01) : 61 - 63
  • [6] ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report
    Gonzalez-Mosquera, Luis F.
    Abu Rous, Fawzi
    Rogers, Alexandra
    Smith, Nicolina
    Goyert, Gregory
    Gadgeel, Shirish
    CLINICAL LUNG CANCER, 2024, 25 (02) : e77 - e80
  • [7] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [8] Brigatinib effective in ALK-positive non-small-cell lung cancer
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (06): : E310 - E310
  • [9] Squamous cell carcinoma of lung in a hen - A case report
    Moregaonkar, SD
    Degloorkar, NM
    Kadam, RD
    INDIAN VETERINARY JOURNAL, 1996, 73 (02): : 237 - 238
  • [10] Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report
    Wang, Yadong
    Wang, Tiange
    Xue, Jianchao
    Jia, Ziqi
    Liu, Xinyu
    Li, Bowen
    Li, Ji
    Li, Xiaoguang
    Wang, Weiwei
    Bing, Zhongxing
    Cao, Lei
    Cao, Zhili
    Liang, Naixin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
12345